Gretchen Brodnicki has been named dean for faculty and research integrity at Harvard Medical School.
Brodnicki is currently director of research compliance for the Partners HealthCare System, and works with faculty and administration at four affiliated teaching hospitals, Brigham and Women’s, Massachusetts General, McLean, and Spaulding.
Before joining Partners, she served as director of research compliance for Beth Israel Deaconess Medical Center. Prior to this, she practiced law privately in the areas of civil litigation and health care, representing clients in intellectual property disputes as well as in corporate, regulatory, and transactional matters with an emphasis on fraud prevention, practice integration, and risk management.
Brodnicki earned a BS in business administration from Gannon University and a JD from Suffolk University Law School in Boston.
Mid-Atlantic region venture capital firm Quaker BioVentures said last week that David King has joined the company as a venture partner.
King has previously served as CEO of three venture-backed life science companies, including BioRexis Pharmaceuticals, which was acquired by Pfizer in 2007, and Principia Pharmaceuticals, which was acquired by Human Genome Sciences. He also served as president of Delsys Pharamceutical, now Elan.
King also previously was a director of Cephalon, 3-Dimensional Pharmaceuticals, and Morphotek. Currently, he serves as chairman of Xencor.
Shantanu Basu has joined Mintz, Levin, Cohn, Ferris, Glovsky and Popeo in the law firm’s West Coast intellectual property practice in Palo Alto, Calif.
Basu represents companies in biotechnology, pharmaceutical, biochip, and related industries. He joins Mintz Levin from Morrison & Foerster. He holds a PhD in molecular biology from Albert Einstein College of Medicine and a JD from Fordham University School of Law.